The efficacy of albuterol/budesonide inhalation spray (Airsupra)

Albuterol/budesonide inhalation spray (Airsupra) is a new aerosol that has been approved by the FDA for the on-demand treatment or prevention of bronchoconstriction and to significantly reduce the risk of severe asthma attacks in patients 18 years of age and older with asthma . The drug combines two active ingredients: albuterol, a short-acting beta2-adrenergic agonist that rapidly relaxes airway smooth muscle, and budesonide, an inhaled corticosteroid that reduces inflammation in the airways. Airsupra is unique in that it is the first approved combination of an inhaled corticosteroid and a short-acting beta-agonist as a reliever treatment, not just a controller treatment, meeting the needs of asthma patients for rapid symptom relief.

Airsupra is administered as two oral inhalations containing 90 mcg of albuterol and 80 mcg of budesonide per inhalation, for a total dose of 180 mcg of albuterol and 160 mcg of budesonide. Patients can use it according to their own asthma symptoms. This flexibility allows patients to get timely relief when acute symptoms occur and is no longer restricted by fixed medication patterns.

In a randomized, double-blind, multicenter study called MANDALA, Airsupra was evaluated for its efficacy in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma. The study found that patients taking Airsupra had a 28% lower risk of first severe asthma attack compared with albuterol alone. This result shows that Airsupra can effectively delay the occurrence of severe attacks and provide patients with more stable disease control.

The main efficacy of Airsupra is that it can effectively relieve asthma symptoms and reduce the frequency of acute attacks, while also providing patients with a safer treatment option. In addition, the drug can help patients better manage asthma in their daily lives and improve their quality of life. However, patients should also be aware of possible side effects when using Airsupra, including headache, oral candida infection, cough and difficulty speaking. This drug should be avoided in patients who are allergic to albuterol, budesonide, or other ingredients. At the same time, patients should not take more than six doses (i.e. 12 inhalations) within a 24-hour period to reduce the risk of side effects.

Overall,Airsupra brings new hope to asthma patients through its unique drug combination and flexible use, especially when rapid relief of acute symptoms and reduced risk of severe attacks is needed. With the widespread use of Airsupra, more patients will be able to enjoy better disease control and improved quality of life.

Reference link:https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-combination-treatment-adults-asthma